Pre-Test Treatment Advances with Novel Anti-Androgen Therapy, PARP Inhibitors, and NGI For Hormone-Sensitive and Castration-Resistant Prostate Cancer Pre-Test Hypertension, hypokalemia, transaminitis, and lower extremity edema are special consideration adverse events for which of the following therapeutics? Abiraterone acetate Apalutamide Docetaxel Enzalutamide Unsure Which of the following best summarizes results from the ARASENS phase 3 trial regarding the use of darolutamide vs placebo in combination with androgen-deprivation therapy and docetaxel in metastatic, hormone-sensitive prostate cancer? The risk of death in the darolutamide group was ~33% lower when compared to placebo and the most common grade 3 or 4 adverse event was hypertension The risk of death in the darolutamide group was ~53% lower when compared to placebo and the most common grade 3 or 4 adverse event was hypertension The risk of death in the darolutamide group was ~33% lower when compared to placebo and the most common grade 3 or 4 adverse event was neutropenia The risk of death in the darolutamide group was ~53% lower when compared to placebo and the most common grade 3-4 adverse event was neutropenia Unsure Olaparib plus abiraterone in metastatic castration-resistant prostate cancer in the PROpel clinical trial yielded which of the following results? The median OS was ~42 months and the most common grade 3-4 adverse event was anemia The median OS was ~62 months and the most common grade 3-4 adverse event was anemia The median OS was ~42 months and the most common grade 3-4 adverse event was neutropenia The median OS was ~62 months and the most common grade 3-4 adverse event was neutropenia Unsure
